COVID-19 Update - This is to inform you that the Government of India has announced a complete lockdown in India 22nd March 2020 to 3rd May 2020. As a result, our offices will now be closed till 3rd May 2020 and all our employees will be working from home. Office telephones will not be answered, and therefore you are requested to direct all your queries related to manuscript submission, review process, publication etc. at below mentioned details. editor@innovativepublication.com, rakesh.its@gmail.com, Mob. 8826373757, 8826859373, 9910947804

Article Access statistics

Viewed: 523

Emailed: 0

PDF Downloaded: 188

Journal of Oral Medicine, Oral Surgery, Oral Pathology and Oral Radiology


Duloxetine- A novel therapeutic regimen for trigeminal neuralgia


Full Text PDF Share on Facebook Share on Twitter


Author Details : Akhilanand Chaurasia

Volume : 3, Issue : 4, Year : 2017

Article Page : 222-224


Suggest article by email

Abstract

Duloxetine is a potent and selective inhibitor of serotonin and noradrenaline transporters and a weak inhibitor of dopamine transporters. Duloxetine is highly protein bound and is widely distributed throughout tissues. It is rapidly and extensively metabolized in the liver by cytochrome P450 (CYP) 1A2 and 2D6 and its numerous metabolites which are inactive are mainly excreted in the urine. It is more effective for recurrent/refractory type of TN. Duloxetine holds the promise in complete remission of TN in future. So in coming days it may be a drug of choice for medical management of TN. This article is an insight in chemical features, pharmacodynamics, pathophysiology and therapeutics of Duloxetine.

Keywords: Antidepressants, Serotonin uptake inhibitors, Trigeminal Neuralgia, Major depressive disorders

How to cite : Chaurasia A, Duloxetine- A novel therapeutic regimen for trigeminal neuralgia. J Oral Med Oral Surg Oral Pathol Oral Radiol 2017;3(4):222-224

Copyright © 2017 by author(s) and J Oral Med Oral Surg Oral Pathol Oral Radiol. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (CC BY 4.0) (creativecommons.org)